704 related articles for article (PubMed ID: 35989085)
1. Immunotherapy for cancer treatment.
Donátová K; Nováková E; Šupolíková M
Klin Onkol; 2022; 35(4):284-289. PubMed ID: 35989085
[TBL] [Abstract][Full Text] [Related]
2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
3. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
4. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy beyond immune checkpoint inhibitors.
Marin-Acevedo JA; Soyano AE; Dholaria B; Knutson KL; Lou Y
J Hematol Oncol; 2018 Jan; 11(1):8. PubMed ID: 29329556
[TBL] [Abstract][Full Text] [Related]
6. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
7. Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (Oenothera biennis) root extract and its active compound oenothein B targeting the PD-1/PD-L1 blockade.
Lee EJ; Kim YS; Kim JH; Woo KW; Park YH; Ha JH; Li W; Kim TI; An BK; Cho HW; Han JH; Choi JG; Chung HS
Phytomedicine; 2024 Mar; 125():155370. PubMed ID: 38266440
[TBL] [Abstract][Full Text] [Related]
8. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in triple-negative breast cancer.
Katz H; Alsharedi M
Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
14. CTLA-4 antibody ipilimumab negatively affects CD4
Rosskopf S; Leitner J; Zlabinger GJ; Steinberger P
Cancer Immunol Immunother; 2019 Aug; 68(8):1359-1368. PubMed ID: 31332464
[TBL] [Abstract][Full Text] [Related]
15. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.
Goleva E; Lyubchenko T; Kraehenbuehl L; Lacouture ME; Leung DYM; Kern JA
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):630-638. PubMed ID: 33716146
[TBL] [Abstract][Full Text] [Related]
16. Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity.
Zhang JC; Chen WD; Alvarez JB; Jia K; Shi L; Wang Q; Zou N; He K; Zhu H
Acta Pharmacol Sin; 2018 Nov; 39(11):1693-1698. PubMed ID: 29991709
[TBL] [Abstract][Full Text] [Related]
17. A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints.
Li Y; Li F; Jiang F; Lv X; Zhang R; Lu A; Zhang G
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27438833
[TBL] [Abstract][Full Text] [Related]
18. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
[TBL] [Abstract][Full Text] [Related]
20. Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?
De Silva P; Aiello M; Gu-Trantien C; Migliori E; Willard-Gallo K; Solinas C
Int J Cancer; 2021 Jul; 149(1):31-41. PubMed ID: 33252786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]